Novartis dumps AveXis program for Rett syndrome after failing repeat round of preclinical testing

26 Oct 2021

Gene TherapyFinancial Statement

Say goodbye to AVXS-201. The Rett syndrome gene therapy drug made by AveXis — the biotech that was bought, kept separate, then renamed and finally absorbed by Novartis into its R&D division — has been dropped by the biopharma. In Novartis’ third quarter financial report, the pharma had found that preclinical data did not support development of the gene therapy into IND-enabling trials and beyond. The announcement comes a year after Novartis told the Rett Society how excited it was by the drug — and its potential benefits and uses.

Organizations

Novartis AG

Novartis Gene Therapies, Inc.

Indications

Rett Syndrome

Targets

Drugs

AVXS-201

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.